Ask about this productRelated genes to: PYCR1 antibody
- Gene:
- PYCR1 NIH gene
- Name:
- pyrroline-5-carboxylate reductase 1
- Previous symbol:
- -
- Synonyms:
- P5C
- Chromosome:
- 17q25.3
- Locus Type:
- gene with protein product
- Date approved:
- 1992-11-24
- Date modifiied:
- 2015-09-07
Related products to: PYCR1 antibody
Related articles to: PYCR1 antibody
- Proline metabolism is selectively altered in cancer cells, providing ATP, redox balance, and proline for cell growth. The final enzyme of proline biosynthesis is Δ-pyrroline-5-carboxylate (P5C) reductase (PYCR), which catalyzes the NAD(P)H-dependent reduction of P5C to proline. Humans have three PYCR isoforms, PYCR1 and PYCR2 in the mitochondrion and PYCR3 in the cytosol. Interest in developing selective inhibitors of PYCR enzymes has significantly increased over the past decade. Orthosteric inhibitors of PYCR1 have been developed, but they may lack specificity given the near identity of the active sites of PYCR1 and PYCR2. Here, we explored a new strategy of targeting noncatalytic cysteines to gain isoform selectivity. Initial results with iodoacetamide showed higher inhibition of PYCR2 relative to PYCR1, a result that was further explored with the thiol-reactive compound ebselen. Ebselen treatment resulted in a complete loss of PYCR2 activity with an IC value of 22 nM, which is 10-fold more sensitive than with PYCR1. Results from protection assays with dithiothreitol, site-directed mutagenesis, and mass spectrometry implicate Cys232 in PYCR2 as the target of ebselen. A new crystal structure of PYCR2 shows that Cys232 is in the P5C-binding loop, whereas PYCR1 contains a serine at this position. Our study provides new insight into the structural and functional roles of unique cysteine residues in PYCR2. Further, our results demonstrate proof-of-concept for targeting a noncatalytic cysteine as a new approach for selectively inhibiting PYCR2 over PYCR1. - Source: PubMed
Publication date: 2026/04/21
Rossman Tyrell CMeeks Kaylen RPurohit GunjanNaldrett Michael JTanner John JBecker Donald F - Pyrroline-5-carboxylate reductase 1 (PYCR1) is a key enzyme in the proline biosynthesis pathway and has garnered widespread attention in the field of tumor research in recent years. Studies have shown that PYCR1 is abnormally expressed in a variety of malignant tumors. It plays a significant role in tumorigenesis and development by participating in metabolic reprogramming of tumor cells, regulating key signaling pathways, influencing the tumor microenvironment, and mediating immune evasion, among other mechanisms. This article systematically reviews the biological structure and functions of PYCR1, its expression characteristics in various tumors, and the underlying molecular mechanisms. The focus is on exploring its role in promoting the occurrence and development of different tumors, as well as its involvement in mediating chemotherapy resistance. Additionally, the research progress and clinical application prospects of PYCR1 as a potential therapeutic target are analyzed, providing a theoretical basis and research directions for the development of novel anti-tumor strategies.
. - Source: PubMed
Meng YuqiYang ZhichangFeng HaimingLi HaitianLi Bin - In this study, we aimed to investigate the effects of PYCR1 and M2-type macrophages on the malignant behaviors of hepatocellular carcinoma (HCC) cells and determine the mechanisms underlying these effects. We induced M2 polarization of macrophages by treating THP-1 cells with interleukin-4 (IL-4) and interleukin-13 (IL-13) and cultured HCC cells with medium conditioned using these macrophages. This co-culture promoted cancer cell invasion, migration, and epithelial–mesenchymal transition, whereas knockdown of pyrroline-5-carboxylic acid reductase 1 (PYCR1) suppressed these malignant behaviors, as well as inhibiting cell proliferation. We further observed that co-culture with M2 macrophage-conditioned medium suppressed apoptosis and ferroptosis of HCC cells; again, PYCR1 knockdown reversed these alterations. In summary, conditioned medium derived from M2 macrophages mediates PYCR1-induced cell proliferation, apoptosis inhibition, and ferroptosis suppression in HCC, ultimately promoting progression of HCC through various signaling pathways. These results indicate the potential of PYCR1 as a therapeutic target for treatment of liver cancer. - Source: PubMed
Publication date: 2026/03/16
Jin XinxinHou YachaoGuo JiayiZhang JunliWu Wenjuan - Hepatoblastoma is a rare pediatric liver cancer, primarily affecting children under three years old. Stemness properties of tumor cells have been linked to tumor recurrence and therapy resistance. Ferroptosis, a form of programmed cell death, plays a role in cancer therapy resistance and is influenced by iron metabolism and lipid peroxidation. - Source: PubMed
Publication date: 2026/03/07
Francés RaquelCasafont ÍñigoDesterke ChristopheMata-Garrido Jorge - Hepatocellular carcinoma (HCC) is a global malignant tumor type. Pyrroline-5-carboxylate reductase 1 (PYCR1) is a metabolic enzyme that exhibits pro-tumor properties in cancer progression. However, the exact molecular mechanism of PYCR1 in HCC progression is still unclear. - Source: PubMed
Zhang JunliHou YachaoJin XinxinGu BiaoWu Wenjuan